Frankfurt - Delayed Quote EUR

Codexis, Inc. (4QK.F)

1.8460

+0.0120

+(0.65%)

At close: April 17 at 9:55:01 PM GMT+2

Codexis Announces Byron Dorgan to Retire from Board of Directors

REDWOOD CITY, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that Byron Dorgan will retire from the Company’s Board of Directors when his current term ends at the 2025 Annual Meeting of Stockholders. Mr. Dorgan joined the Board in 2011, served as Chairman from 2021 through 2024, and currently serves as the Chair of the Nominating and Corporate Governance Comm

GlobeNewswire 10 days ago

CDXS
Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last?

Arcutis Biotherapeutics (ARQT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks 16 days ago

ARQT

CDXS
Codexis Appoints Cynthia Collins to Board of Directors

REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Cynthia Collins to the Company’s Board of Directors. “I am thrilled to welcome Cindy to our Board,” said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. “She has been at the forefront of innovation across multiple therapeutic modalities and brings a weal

GlobeNewswire 18 days ago

CDXS
Codexis Announces First Revenue-Generating Contract for ECO Synthesis™ Manufacturing Services

Represents first project to enter the ECO Synthesis™ Innovation Lab Core enzymes for ECO Synthesis™ technology have transitioned from research into development and scale-up as the first step in securing the raw materials supply chain REDWOOD CITY, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced its first revenue-generating contract to manufacture siRNA materia

GlobeNewswire 26 days ago

CDXS
Codexis Announces New Employment Inducement Grants

REDWOOD CITY, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis’ Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 10,000 shares of Codexis common stock and (ii) 5,000 restricted stock un

GlobeNewswire last month

CDXS
When Will Codexis, Inc. (NASDAQ:CDXS) Become Profitable?

We feel now is a pretty good time to analyse Codexis, Inc.'s ( NASDAQ:CDXS ) business as it appears the company may be...

Simply Wall St. last month

CDXS
Q4 2024 Codexis Inc Earnings Call

Q4 2024 Codexis Inc Earnings Call

Thomson Reuters StreetEvents last month

CDXS

PFE
Codexis Inc (CDXS) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Revenue Growth ...

Codexis Inc (CDXS) outlines a path to profitability with new agreements and the ECO Synthesis platform, despite a dip in annual revenue and ongoing net losses.

GuruFocus.com last month

CDXS
Codexis (CDXS) Reports Q4 Loss, Misses Revenue Estimates

Codexis (CDXS) delivered earnings and revenue surprises of -550% and 26.65%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

CDXS
Codexis: Q4 Earnings Snapshot

The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 2 cents per share. The producer of custom industrial enzymes posted revenue of $21.5 million in the period, which also fell short of Street forecasts. Four analysts surveyed by Zacks expected $29.3 million.

Associated Press Finance last month

CDXS
Codexis Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Total revenue of $59.3 million for the fiscal year ended December 31, 2024 Expect double digit growth for total revenue in 2025 2025 to demonstrate acceleration of commercial growth through double-stranded RNA ligase and GLP-grade siRNA material; expect to secure GMP scale-up partner REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced financial result

GlobeNewswire last month

CDXS
Codexis to Participate in TD Cowen 45th Annual Health Care Conference

REDWOOD CITY, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will attend the TD Cowen 45th Annual Health Care Conference, being held March 3-5, 2025, in Boston, Massachusetts. Management will participate in a fireside chat on Tuesday, March 4, 2025, at 1:10 pm ET. A live webcast of the event will be available in the Investor Relations section of th

GlobeNewswire last month

CDXS
Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th

REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the fourth quarter and fiscal year 2024 on Thursday, February 27, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business upd

GlobeNewswire 2 months ago

CDXS
Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board

REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Arthur Levin, PhD, to the Company’s Strategic Advisory Board (SAB). Dr. Levin is a founding member of Avidity Biosciences, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called antibody oligonucleotide conjugates, and currently serves on its Boa

GlobeNewswire 2 months ago

CDXS
Codexis (NASDAQ:CDXS) investors are sitting on a loss of 79% if they invested three years ago

It's not possible to invest over long periods without making some bad investments. But you want to avoid the really big...

Simply Wall St. 2 months ago

CDXS
Codexis Appoints Christos Richards to Board of Directors

Christos Richards Christos Richards appointed to Codexis Board of Directors. REDWOOD CITY, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Christos Richards to the Company’s Board of Directors. “I am delighted to welcome Christos to our Board. His broad and deep knowledge and understanding of the life sciences industry will be invaluable as w

GlobeNewswire 3 months ago

CDXS
Is There An Opportunity With Codexis, Inc.'s (NASDAQ:CDXS) 22% Undervaluation?

Key Insights Codexis' estimated fair value is US$6.07 based on 2 Stage Free Cash Flow to Equity Codexis' US$4.76 share...

Simply Wall St. 3 months ago

CDXS
Codexis, Inc.'s (NASDAQ:CDXS) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week

Key Insights Institutions' substantial holdings in Codexis implies that they have significant influence over the...

Simply Wall St. 4 months ago

CDXS
Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference

REDWOOD CITY, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will attend the Piper Sandler 36th Annual Healthcare Conference, being held December 3-5, 2024, in New York, New York. Management will participate in a fireside chat on Tuesday, December 3, 2024, at 11:00 am ET. A live webcast of the event will be available in the Investor Relations secti

GlobeNewswire 4 months ago

CDXS
Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics

—Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset— —Joint poster with Bachem demonstrates superiority of Company’s double-stranded RNA ligases compared to wild-type enzymes— —Management to host conference call today at 4:30 pm EST to discuss data— REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced data f

GlobeNewswire 5 months ago

CDXS

Performance Overview

Return	4QK.F	S&P 500 (^GSPC)
YTD	-61.27%	-10.18%
1-Year	-27.89%	+5.19%
3-Year	-89.00%	+20.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Codexis, Inc. (4QK.F)

Codexis Announces Byron Dorgan to Retire from Board of Directors

Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last?

Codexis Appoints Cynthia Collins to Board of Directors

Codexis Announces First Revenue-Generating Contract for ECO Synthesis™ Manufacturing Services

Codexis Announces New Employment Inducement Grants

When Will Codexis, Inc. (NASDAQ:CDXS) Become Profitable?

Q4 2024 Codexis Inc Earnings Call

Codexis Inc (CDXS) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Revenue Growth ...

Codexis (CDXS) Reports Q4 Loss, Misses Revenue Estimates

Codexis: Q4 Earnings Snapshot

Codexis Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Codexis to Participate in TD Cowen 45th Annual Health Care Conference

Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th

Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board

Codexis (NASDAQ:CDXS) investors are sitting on a loss of 79% if they invested three years ago

Codexis Appoints Christos Richards to Board of Directors

Is There An Opportunity With Codexis, Inc.'s (NASDAQ:CDXS) 22% Undervaluation?

Codexis, Inc.'s (NASDAQ:CDXS) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week

Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference

Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics

Performance Overview